Matthew Dankner

1.9k total citations · 2 hit papers
29 papers, 747 citations indexed

About

Matthew Dankner is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Matthew Dankner has authored 29 papers receiving a total of 747 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Matthew Dankner's work include Melanoma and MAPK Pathways (9 papers), Brain Metastases and Treatment (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Matthew Dankner is often cited by papers focused on Melanoma and MAPK Pathways (9 papers), Brain Metastases and Treatment (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Matthew Dankner collaborates with scholars based in Canada, United States and Spain. Matthew Dankner's co-authors include April A. N. Rose, Peter M. Siegel, Shivshankari Rajkumar, Ian R. Watson, Richard S. Blumberg, Scott D. Gray‐Owen, Yu‐Hwa Huang, Nicole Beauchemin, Kevin Petrecca and Pierre Fiset and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Cancer Research.

In The Last Decade

Matthew Dankner

26 papers receiving 731 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations

2018 348 citations Matthew Dankner, April A. N. Rose et al. profile →
Neoadjuvant Chemoimmunotherapy for NSCLC

2024 89 citations Mark Sorin, Connor Prosty et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew Dankner Canada	12	390	374	222	152	119	29	747
J. Rafael Sierra United States	11	582 1.5×	364 1.0×	249 1.1×	131 0.9×	133 1.1×	18	1.1k
Luca Lazzari Italy	14	446 1.1×	433 1.2×	190 0.9×	162 1.1×	261 2.2×	25	853
Elena Poddubskaya Russia	16	312 0.8×	478 1.3×	269 1.2×	78 0.5×	236 2.0×	57	846
Young‐Kwang Yoon South Korea	13	412 1.1×	442 1.2×	203 0.9×	99 0.7×	104 0.9×	22	736
Rosalin Mishra United States	11	421 1.1×	345 0.9×	139 0.6×	56 0.4×	81 0.7×	20	724
Nyam Kamsu-Kom France	10	662 1.7×	615 1.6×	117 0.5×	84 0.6×	80 0.7×	12	1.0k
Meredith Pelster United States	9	311 0.8×	556 1.5×	149 0.7×	123 0.8×	157 1.3×	29	832
Alberto Servetto Italy	16	512 1.3×	394 1.1×	271 1.2×	75 0.5×	208 1.7×	56	897
Simon Vyse United Kingdom	15	532 1.4×	489 1.3×	525 2.4×	80 0.5×	219 1.8×	17	1.1k
Raul Ayala United States	9	483 1.2×	356 1.0×	253 1.1×	69 0.5×	124 1.0×	18	830

Countries citing papers authored by Matthew Dankner

Since Specialization

Citations

This map shows the geographic impact of Matthew Dankner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Dankner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Dankner more than expected).

Fields of papers citing papers by Matthew Dankner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Dankner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Dankner. The network helps show where Matthew Dankner may publish in the future.

Co-authorship network of co-authors of Matthew Dankner

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Dankner. A scholar is included among the top collaborators of Matthew Dankner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Dankner. Matthew Dankner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dankner, Matthew, Mark Sorin, Jamie Magrill, et al.. (2025). Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis. Current Oncology. 32(11). 624–624.

Dankner, Matthew, Charles Vincent Rajadurai, Peter Tai, et al.. (2025). Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers. JCO Precision Oncology. 9(9). e2400199–e2400199. 1 indexed citations

Pierre, Kevin, Tariq Al‐Saadi, Caroline Reinhold, et al.. (2024). Machine learning prediction of brain metastasis invasion pattern on brain magnetic resonance imaging scans. Neuro-Oncology Advances. 6(1). vdae200–vdae200.

Bouganim, Nathaniel, et al.. (2024). Antibody–Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases. Current Oncology. 31(10). 6314–6342. 2 indexed citations

Dankner, Matthew, David W. Cescon, Anna Spreafico, et al.. (2024). The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers. Cancers. 16(2). 445–445. 7 indexed citations

Dankner, Matthew, Victor Cohen, Lawrence Panasci, et al.. (2024). The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre. Current Oncology. 32(1). 1–1. 3 indexed citations

Maritan, Sarah M., Zhimin Zeng, Zhengfei Zhu, et al.. (2024). Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis. Heliyon. 10(9). e29668–e29668. 5 indexed citations

Sorin, Mark, Connor Prosty, Matthew Dankner, et al.. (2024). Neoadjuvant Chemoimmunotherapy for NSCLC. JAMA Oncology. 10(5). 621–621. 89 indexed citations breakdown →

Soria‐Bretones, Isabel, et al.. (2024). The role of CRAF in cancer progression: from molecular mechanisms to precision therapies. Nature reviews. Cancer. 24(2). 105–122. 20 indexed citations

10.

Guaitoli, Giorgia, Lodovica Zullo, Marcello Tiseo, et al.. (2023). Non-small-cell lung cancer: how to manage BRAF-mutated disease. Drugs in Context. 12. 1–19. 19 indexed citations

11.

Romero, Joan Miguel, Mark Sorin, Matthew Dankner, et al.. (2023). Gender Disparities in Academic Outcomes Among Graduates of a Canadian MD-PhD Program. Clinical and investigative medicine. 46(1). E4–E14. 1 indexed citations

12.

Rajkumar, Shivshankari, LeeAnn Ramsay, Mathieu Lajoie, et al.. (2022). Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. Cell Reports. 39(1). 110634–110634. 16 indexed citations

13.

Lewis, Kyle, Alexander Kiepas, Julien Senécal, et al.. (2020). p66ShcA functions as a contextual promoter of breast cancer metastasis. Breast Cancer Research. 22(1). 7–7. 12 indexed citations

14.

Whittaker, Heather, et al.. (2020). An exercise in scientific writing for physicians in training. Clinical and investigative medicine. 43(1). E35–E38.

15.

Dankner, Matthew, Véronique Ouellet, Laudine Communal, et al.. (2019). CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis. American Journal Of Pathology. 189(7). 1451–1461. 9 indexed citations

16.

Dankner, Matthew, et al.. (2019). A Survey of Health Care Professionals and Oncology Patients at the Mcgill University Health Centre Reveals Enthusiasm for Establishing a Postmortem Rapid Tissue Donation Program. Current Oncology. 26(4). 558–570. 3 indexed citations

17.

Dankner, Matthew, Mathieu Lajoie, Dan Moldoveanu, et al.. (2018). Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. Clinical Cancer Research. 24(24). 6483–6494. 47 indexed citations

18.

Bernier, Cynthia, Michel Gravel, Matthew Dankner, et al.. (2018). DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. Anti-Cancer Drugs. 29(8). 774–785. 16 indexed citations

19.

Dankner, Matthew. (2018). Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology. JCO Precision Oncology. 2(2). 1–12. 15 indexed citations

20.

Dankner, Matthew, Scott D. Gray‐Owen, Yu‐Hwa Huang, Richard S. Blumberg, & Nicole Beauchemin. (2017). CEACAM1 as a Multi-Purpose Target for Cancer Immunotherapy. OncoImmunology. 6(7). 0–0. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact